LORIA, Paola
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 29.549
AS - Asia 11.727
EU - Europa 10.003
SA - Sud America 1.505
AF - Africa 226
Continente sconosciuto - Info sul continente non disponibili 175
OC - Oceania 27
Totale 53.212
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 28.954
SG - Singapore 3.588
CN - Cina 3.369
GB - Regno Unito 3.174
IT - Italia 1.751
HK - Hong Kong 1.493
BR - Brasile 1.146
DE - Germania 997
VN - Vietnam 985
SE - Svezia 966
FI - Finlandia 746
UA - Ucraina 572
BD - Bangladesh 548
TR - Turchia 532
FR - Francia 405
RU - Federazione Russa 402
PL - Polonia 373
KR - Corea 306
CA - Canada 274
BG - Bulgaria 213
IN - India 213
AR - Argentina 125
MX - Messico 97
IQ - Iraq 87
NL - Olanda 87
ID - Indonesia 81
JP - Giappone 81
PK - Pakistan 54
ZA - Sudafrica 54
ES - Italia 51
EC - Ecuador 49
VE - Venezuela 48
AE - Emirati Arabi Uniti 46
CR - Costa Rica 42
MY - Malesia 41
CO - Colombia 37
BE - Belgio 36
HN - Honduras 34
PH - Filippine 33
TW - Taiwan 33
CL - Cile 32
MA - Marocco 32
UZ - Uzbekistan 32
AT - Austria 30
JM - Giamaica 29
IE - Irlanda 26
LT - Lituania 26
SA - Arabia Saudita 25
EG - Egitto 24
CZ - Repubblica Ceca 23
JO - Giordania 23
PY - Paraguay 23
SC - Seychelles 21
GR - Grecia 20
GT - Guatemala 19
IL - Israele 19
RO - Romania 19
SV - El Salvador 19
NI - Nicaragua 18
AU - Australia 17
BO - Bolivia 16
NP - Nepal 16
PE - Perù 16
TH - Thailandia 16
DZ - Algeria 15
IR - Iran 15
TT - Trinidad e Tobago 15
AZ - Azerbaigian 14
KE - Kenya 14
CW - ???statistics.table.value.countryCode.CW??? 13
ET - Etiopia 13
OM - Oman 13
TN - Tunisia 12
CH - Svizzera 11
NG - Nigeria 10
PR - Porto Rico 10
UY - Uruguay 10
AL - Albania 9
BY - Bielorussia 9
DO - Repubblica Dominicana 9
KZ - Kazakistan 9
SI - Slovenia 9
RS - Serbia 8
EU - Europa 7
GE - Georgia 7
GP - Guadalupe 7
NZ - Nuova Zelanda 7
BB - Barbados 6
LB - Libano 6
PA - Panama 6
SN - Senegal 6
AM - Armenia 5
BA - Bosnia-Erzegovina 5
HU - Ungheria 5
QA - Qatar 5
SK - Slovacchia (Repubblica Slovacca) 5
UG - Uganda 5
AO - Angola 4
BH - Bahrain 4
CY - Cipro 4
Totale 52.976
Salva come PNG Salva come JPEG
Città #
Ashburn 3.901
Singapore 2.438
Fairfield 2.193
Santa Clara 2.135
Southend 2.017
Woodbridge 1.602
Hong Kong 1.476
San Jose 1.317
Houston 1.305
Jacksonville 1.232
Chandler 1.197
Hefei 1.151
Seattle 848
Wilmington 805
Dearborn 798
Ann Arbor 776
Cambridge 722
Council Bluffs 665
Beijing 613
Chicago 595
Nyköping 546
Los Angeles 531
London 523
Helsinki 508
Warsaw 359
New York 325
The Dalles 313
Ho Chi Minh City 310
Modena 308
Seoul 289
Izmir 285
San Diego 243
Hanoi 237
Princeton 226
Sofia 207
Salt Lake City 206
São Paulo 205
Eugene 201
Milan 190
Boardman 185
Des Moines 172
Lauterbourg 167
Columbus 162
Buffalo 156
Dallas 150
Munich 139
Shanghai 135
Tampa 132
Moscow 124
Rome 113
Grafing 101
Elk Grove Village 96
Falls Church 86
North Bergen 80
Orem 79
Phoenix 74
Toronto 71
Washington 64
Bremen 58
Sterling 57
Guangzhou 53
Tokyo 53
Atlanta 50
Brooklyn 48
Kunming 48
Da Nang 47
Frankfurt am Main 46
Montreal 46
Istanbul 44
Jakarta 43
Miami 43
Baghdad 41
Lancaster 41
Bologna 40
Redwood City 39
San Francisco 39
Denver 38
Detroit 38
Rio de Janeiro 38
Turku 38
Haiphong 37
Mexico City 36
Naples 36
Norwalk 36
Manchester 34
San Mateo 34
Amsterdam 32
Fremont 32
Kent 31
Philadelphia 30
Bari 29
Brussels 29
Chennai 29
San José 27
Dulles 26
Falkenstein 25
Tashkent 25
Johannesburg 24
Verona 24
Biên Hòa 23
Totale 37.671
Salva come PNG Salva come JPEG
Nome #
ABCB4 and ABCB11 mutations in intrahepatic cholestasis of pregnancy in an Italian population 746
Differential effect of oleic and palmitic acid on lipid accumulation and apoptosis in cultured hepatocytes 551
Increased appearance rate of 27-hydroxycholesterol in vivo in hypercholesterolemia: A possible compensatory mechanism. 483
Neoangiogenesis-related genes are hallmarks of fast-growing hepatocellular carcinomas and worst survival. Results from a prospective study 464
Effect of liver cirrhosis on the systemic availability of naltrexone in humans 453
Nonalcoholic Fatty Liver Disease in HIV-Infected Patients Referred to a Metabolic Clinic: Prevalence, Characteristics, and Predictors 445
Gender, fatty liver and GGT 432
Review article: diabetes, genetics and ethnicity 431
Decreased hepatic expression of PPAR-gamma coactivator-1 in cholesterol cholelithiasis. 426
Human Immunodeficiency Virus Is the Major Determinant of Steatosis and Hepatitis C Virus of Insulin Resistance in Virus-associated Fatty Liver Disease. 408
Review article: the metabolic syndrome and non-alcoholic fatty liver disease 401
Prophylaxis of venous thromboembolism in elderly patients with multimorbidity 400
Suppression of bile acid synthesis, but not of hepatic cholesterol 7alpha-hydroxylase expression, by obstructive cholestasis in humans 393
Is nonalcoholic steatohepatitis associated with a high-though-normal thyroid stimulating hormone level and lower cholesterol levels? 388
Genetic determinants of susceptibility and severity in nonalcoholic fatty liver disease. 387
Age-associated alterations in cholesterol homeostasis: evidence from a cross-sectional study in a Northern Italy population. 383
Adherence to antibiotic treatment guidelines and outcomes in the hospitalized elderly with different types of pneumonia 374
Correlation between plasma levels of 7alpha-hydroxy-4-cholesten-3-one and cholesterol 7alpha-hydroxylation rates in vivo in hyperlipidemic patients 368
Herpesvirus DNA is frequently detected in liver tissue from hepatitis C patients 365
Effects of bile duct ligation and cholic acid treatment on fatty liver in two rat models of non-alcoholic fatty liver disease 364
Genetic polymorphisms in non-alcoholic fatty liver disease: Interleukin-6-174G/C polymorphism is associated with non-alcoholic steatohepatitis 360
Endocrine and liver interaction: the role of endocrine pathways in NASH 359
Practice guidelines for the diagnosis and management of nonalcoholic fatty liver disease. A decalogue from the Italian Association for the Study of the Liver (AISF) Expert Committee. 358
Classical and innovative insulin sensitizing drugs for the prevention and treatment of NAFLD 357
Non-organ-specific autoantibodies in nonalcoholic fatty liver disease: Prevalence and correlates 351
In Vivo Degradation of Cholesterol to Bile Acids Is Reduced in Patients Receiving Parenteral Nutrition. 350
Short-term effects of simvastatin on bile acid synthesis and biliary lipid secretion in human subjects. 349
Hepatitis C virus-infected patients are 'spared' from the metabolic syndrome but not from insulin resistance. A comparative study of nonalcoholic fatty liver disease and hepatitis C virus-related steatosis 348
Nonalcoholic fatty liver disease and aging: epidemiology to management 346
Effect of the selective expansion of cholic acid pool on bile lipid composition: possible mechanism of bile acid induced biliary cholesterol desaturation. 341
Comparative cytotoxic and cytoprotective effects of taurohyodeoxycholic acid (THDCA) and tauroursodeoxycholic acid (TUDCA) in HepG2 cell line. 339
Cardiovascular risk, lipidemic phenotype and steatosis. A comparative analysis of cirrhotic and non-cirrhotic liver disease due to varying etiology. 337
Statins in liver disease: a molehill, an iceberg, or neither? 336
'True' antimitochondrial antibody-negative primary biliary cirrhosis, low sensitivity of the routine assays, or both? 335
Regulation of bile acid synthesis in humans: effect of treatment with bile acids, cholestyramine or simvastatin on cholesterol 7 alpha-hydroxylation rates in vivo. 335
Liver and kidney foreign bodies granulomatosis in a patient with malocclusion, bruxism, and worn dental prostheses 332
Anatomia e fisiologia delle vie biliari 330
Il pool degli acidi biliari quale regolatore del metabolismo epatico del colesterolo: sintesi degli acidi biliari. 327
Hepatocellular carcinoma in a patient treated with efalizumab for psoriasis. 324
Nuclear receptors as potential molecular targets in cholesterol accumulation conditions: Insights from evidence on hepatic cholesterol degradation and gallstone disease in humans 323
ESTIMATION OF CARDIOVASCULAR RISK IN TYPE 2 DIABETES 322
Natural history of gallstone disease: Expectant management or active treatment? Results from a population-based cohort study. 320
Is liver fat detrimental to vessels?: intersections in the pathogenesis of NAFLD and atherosclerosis 319
Diet and gallstones in Italy: the cross-sectional MICOL results. 317
If steatosis is the atherosclerosis of the liver, are statins the "aspirin" for steatosis? 316
'Endocrine NAFLD' a hormonocentric perspective of nonalcoholic fatty liver disease pathogenesis 314
Chronic hepatitis C virus infection and atherosclerosis: Clinical impact and mechanisms. 314
Short-term multidisciplinary non-pharmacological intervention is effective in reducing liver fat content assessed non-invasively in patients with nonalcoholic fatty liver disease (NAFLD) 314
Multiecho MR sequences and high-resolution magic angle spinning (HRMAS)ex-vivo spectroscopy in the qualitative analysis and differentiationbetween steatohepatitis and steatosis 313
Relationship of serum fetuin-a levels with coronary atherosclerotic burden and NAFLD in patients undergoing elective coronary angiography. 313
Risk for cardiovascular events in an Italian population of patients with type 2 diabetes 308
MR techniques in the qualitative analysis of liver steatosis: the potential in the differentiation between steatohepatatis and steatosis 307
NAFLD AND TYPE 2 DIABETES: A GENETIC OR METABOLIC ISSUE? 307
From NAFLD in clinical practice to answers from guidelines. 307
Advances in the comprehension of the pathophysiology of bile secretion 303
Chicken or egg turned into head or belly 302
Alpha but not beta interferon is useful in chronic active hepatitis due to hepatitis C virus - A prospective, double-blind, randomized study 302
Is cholangiocarcinoma another complication of insulin resistance: A report of three cases 302
Ultrasonographic fatty liver indicator, a novel score which rules out NASH and is correlated with metabolic parameters in NAFLD. 302
HEPATIC EXPRESSION OF NUCLEAR RECEPTORS AND BILIARY TRANSPOTERS IN HUMAN CHOLESTEROL GALLSTONE DISEASE. 302
Hepatic nuclear receptors in human cholelithiasis: A link with insulin resistance? 300
Effects of acute changes of bile acid pool composition on biliary lipid secretion 299
Apolipoprotein synthesis in nonalcoholic steatohepatitis 299
Non-alcoholic fatty liver disease (NAFLD) and cardiovascular disease: An open question 299
Magnetic resonance for quantitative assessment of liver steatosis: a new potential tool to monitor antiretroviral-drug-related toxicities. 299
MOLECULAR REGULATION OF STEROL METABOLISM BY BILE ACIDS IN CULTURED HUMAN HEPATOCYTES 296
Treatment of atherogenic liver based on the pathogenesis of nonalcoholic Fatty liver disease: a novel approach to reduce cardiovascular risk? 295
Cardiovascular and systemic risk in nonalcoholic fatty liver disease -Atherosclerosis as a major player in the natural course of NAFLD 294
Bile acid structure and regulation of biliary protein secretion and composition in man 293
HEPATIC NUCLEAR RECEPTOR EXPRESSION AND REGULATION OF BILE ACID SYNTHESIS IN HUMANS 293
Pathogenesis and significance of hepatitis C virus steatosis: An update on survival strategy of a successful pathogen 293
Effect of ursocholic acid on bile lipid secretion and composition 292
Fasting insulin and uric acid levels but not indices of iron metabolism are independent predictors of non-alcoholic fatty liver disease. A case-control study 290
Determinants of bile secretion: effect of bile salt structure on bile flow and biliary cation secretion 290
Bile acid feeding and hepatic sterol metabolism: effect of deoxycholic acid. 286
Effect of taurohyodeoxycholic acid on biliary lipid secretion in humans 282
Review article: hepatic steatosis and insulin resistance 282
Drug metabolism in liver cirrhosis: alterations of the time-course of plasma naltrexone levels after oral intake 280
α1-antitrypsin mutations in NAFLD: High prevalence and association with altered iron metabolism but not with liver damage 279
Risk of cardiovascular, cardiac and arrhythmic complications in patients with non-alcoholic fatty liver disease. 279
Nonalcoholic fatty liver disease induced by leuprorelin acetate 277
Patogenesi della colelitiasi. I. Colelitiasi colesterinica. 276
Hepatitis C and diabetes: the inevitable coincidence? 276
Cholesterol absorption in cirrhosis: the role of total and individual bile acid pool size 274
Clinical physiology of NAFLD: A critical overview of pathogenesis and treatment 274
MR techiniques in the quantitative assessment of liver steatosis 273
The effect of chenodeoxycholic acid (CDCA) on cholesterol absorption. 271
Non-alcoholic Fatty Liver Disease: a HR-MAS analysis 271
Risk factors for hospital readmission of elderly patients 271
Incidence of gallstone disease in Italy: Results from a multicenter, population-based Italian study (the MICOL project) 268
Influence of age on bile acid synthesis: Role of hepatic expression of nuclear receptors 267
Intestinal solubilization, absorption, pharmacokinetics and bioavailability of chenodeoxycholic acid. 265
Influence of age and sex on serum concentrations of total dimeric activin A 264
Growth hormone plasma levels in nonalcoholic fatty liver disease 263
Fisiologia della secrezione biliare. 263
The prediction of coronary heart disease mortality as a function of major risk factors in over 30.000 men in the italian RIFLE Pooling Project. A comparison with the MRFIT primary screenees 262
Do diabetes and obesity promote hepatic fibrosis in familial heterozygous hypobetalipoproteinemia? 262
Gli enzimi epatobiliari nella diagnostica clinica delle Epatopatie. 261
Steatosis and hepatitis C virus: mechanisms and significance for hepatic and extrahepatic disease 260
Effect of diabetic autonomic neuropathy on gallbladder kinetics in insulin dependent diabetic patients 259
Totale 32.880
Salva come PNG Salva come JPEG
Categoria #
all - tutte 201.991
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 201.991
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20222.323 0 0 0 0 87 156 261 204 392 213 607 403
2022/20233.279 363 354 205 326 401 583 72 310 385 29 142 109
2023/20242.003 84 119 114 136 457 221 216 286 56 42 75 197
2024/20257.463 263 87 129 495 1.607 971 588 413 707 257 838 1.108
2025/202616.044 897 613 1.224 1.896 2.968 1.580 1.933 628 1.369 1.138 992 806
2026/20275.288 389 931 1.271 2.533 164 0 0 0 0 0 0 0
Totale 53.212